» Articles » PMID: 35928868

The Functions of Long Noncoding RNAs on Regulation of F-box Proteins in Tumorigenesis and Progression

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Aug 5
PMID 35928868
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulated evidence has revealed that F-box protein, a subunit of SCF E3 ubiquitin ligase complexes, participates in carcinogenesis and tumor progression targeting its substrates for ubiquitination and degradation. F-box proteins could be regulated by cellular signaling pathways and noncoding RNAs in tumorigenesis. Long noncoding RNA (lncRNA), one type of noncoding RNAs, has been identified to modulate the expression of F-box proteins and contribute to oncogenesis. In this review, we summarize the role and mechanisms of multiple lncRNAs in regulating F-box proteins in tumorigenesis, including lncRNAs SLC7A11-AS1, MT1JP, TUG1, FER1L4, TTN-AS1, CASC2, MALAT1, TINCR, PCGEM1, linc01436, linc00494, GATA6-AS1, and ODIR1. Moreover, we discuss that targeting these lncRNAs could be helpful for treating cancer modulating F-box protein expression. We hope our review can stimulate the research on exploration of molecular insight into how F-box proteins are governed in carcinogenesis. Therefore, modulation of lncRNAs is a potential therapeutic strategy for cancer therapy regulation of F-box proteins.

Citing Articles

FBXL18 is required for ovarian cancer cell proliferation and migration through activating AKT signaling.

Zhuang Y, Xue J, Qiu X, Zhu Y, Lv J, Xia F Am J Transl Res. 2024; 16(5):1977-1990.

PMID: 38883375 PMC: 11170572. DOI: 10.62347/HHXX8166.


Prognostic significance of long noncoding RNA TTN-AS1 in various malignancies.

Lin G, Liu X, Cong C, Xu L Cancer Rep (Hoboken). 2023; 6(10):e1876.

PMID: 37528740 PMC: 10598252. DOI: 10.1002/cnr2.1876.


Association of lncRNA H19 polymorphisms with cancer susceptibility: An updated meta-analysis based on 53 studies.

Yuan Y, Wang Y, Niu X, Han Y, Li W, Cheng M Front Genet. 2023; 13:1051766.

PMID: 36588790 PMC: 9794744. DOI: 10.3389/fgene.2022.1051766.

References
1.
Zhou H, Liu Y, Zhu R, Ding F, Wan Y, Li Y . FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene. 2017; 36(23):3312-3321. PMC: 5926769. DOI: 10.1038/onc.2016.479. View

2.
Zhang S, Xu J, Chen Q, Zhang F, Wang H, Guo H . lncRNA MT1JP-overexpression abolishes the silencing of PTEN by miR-32 in hepatocellular carcinoma. Oncol Lett. 2021; 22(2):604. PMC: 8227557. DOI: 10.3892/ol.2021.12865. View

3.
He S, Yang S, Zhang Y, Li X, Gao D, Zhong Y . LncRNA ODIR1 inhibits osteogenic differentiation of hUC-MSCs through the FBXO25/H2BK120ub/H3K4me3/OSX axis. Cell Death Dis. 2019; 10(12):947. PMC: 6906393. DOI: 10.1038/s41419-019-2148-2. View

4.
Liu F, Hu L, Pei Y, Zheng K, Wang W, Li S . Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis. BMC Cancer. 2020; 20(1):258. PMC: 7106910. DOI: 10.1186/s12885-020-6665-2. View

5.
Fang J, Huang C, Ke J, Li J, Zhang W, Xue H . lncRNA TTN-AS1 facilitates proliferation, invasion, and epithelial-mesenchymal transition of breast cancer cells by regulating miR-139-5p/ZEB1 axis. J Cell Biochem. 2020; 121(12):4772-4784. DOI: 10.1002/jcb.29700. View